Zipalertinib in Non-Small Cell Lung Cancer: NCT07802834 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Not yet recruiting
Recruitment status
42
Planned enrollment
2028-12-01
Primary-completion proxy
Executive view
NCT07802834 evaluates Zipalertinib in Non-Small Cell Lung Cancer. The disclosed sponsor is Stanford University, the design is Interventional, and the geographic footprint is Geography not reported. The first listed primary endpoint is Molecular response rate at 12 weeks, assessed over 12 weeks.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07802834 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Non-Small Cell Lung Cancer landscape. Drug & Asset MCP drug_fetch was queried for Zipalertinib, while Company & Deal Intelligence MCP organization_fetch was queried for Stanford University.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07802834 | Zipalertinib | Phase 2 / Not yet recruiting | Stanford University | Geography not reported | Molecular response rate at 12 weeks 12 weeks | 2028-12-01 |
| NCT07809256 | Pembrolizumab | Phase 3 / Recruiting | Sponsor not reported | Russia | Progression-Free Survival (PFS) Up to 48 months. | 2028-08-01 |
| NCT07806773 | TUB-040 | Phase 2 / Not yet recruiting | Tubulis GmbH | United States | Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) From enrollment until 30 days after last dose of study drug | 2029-05-01 |
| NCT07807722 | Anlotinib Dihydrochloride | Phase 2 / Not yet recruiting | Hubei Cancer Hospital | China | MPR rate At the time of definitive surgery | 2028-03-01 |
| NCT07808138 | Cemiplimab-RWLC | Phase 2 / Not yet recruiting | Netherlands Cancer Insitute | Netherlands | Recurrence free survival (RFS) as per RECIST 1.1 24 months | 2029-12-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07802834 is a Phase 2, not yet recruiting study with 42 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.
The primary endpoint is “Molecular response rate at 12 weeks” over “12 weeks.” The retrieved endpoint description is: To measure the molecular response rate at 12 weeks of adjuvant zipalertinib in the Treatment MRD+ Arm..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 42 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Non-Small Cell Lung Cancer. These records do not establish direct evidence for NCT07802834 unless the registration number matches.
ASTRES: A Phase 2, Single-Arm Study of Atezolizumab in Locally Advanced, Unresectable, Stage III, Non-Small Cell Lung Cancer
Phase 2; n=127; PFS(IRF-assessed 12-month) = 54.9 % ( 46.0 - 63.7) Source: https://cattendee.abstractsonline.com/meeting/21487/Session/124
First-Line Chemoimmunotherapy and Chemotherapy Outcomes in RET Fusion-Positive Lung Cancer Patients in LIBRETTO-431
Phase 3; n=102; mPFS: P-Value = 0.8; mPFS = 11.0 month ( 11.0 - 17.0) Source: https://cattendee.abstractsonline.com/meeting/21487/Session/187
Updated Peri-R-02: Outcomes of Neoadjuvant ICI-Based Therapy Versus Chemotherapy in Resectable Driver-Negative NSCLC
Not Applicable; n=422; EFS(24-month) = 61.2 % ; EFS(24-month) = 76.7 % Source: https://cattendee.abstractsonline.com/meeting/21487/Session/175
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Zipalertinib is indexed as Small molecule drug with EGFR exon 20 biology and a global stage of NDA/BLA. The asset profile lists Taiho Pharmaceutical Co., Ltd. as an originator or developer.
No exact Company & Deal Intelligence profile was returned for Stanford University. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Zipalertinib is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07802834
Protocol source: https://clinicaltrials.gov/study/NCT07802834
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.
Zipalertinib in Non-Small Cell Lung Cancer is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Molecular response rate at 12 weeks and 2028-12-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
